Skip to content

Hottest Stocks in CW 21/21

Last week people traded for all it was worth on wikifolio.com. Find out here which stocks were bought and sold in particular large numbers and which motives were decisive for this.

Last week's hottest stocks - charts and a magnifying glass
Source: Nataliya Vaitkevich, pexels.com

Fear of Missing Out: Buying when prices rise

# Name Performance 7 days bought in this wikifolio, among others
1 Verbio 18,2% Trendfolge Long/Short Smallcap
2 GameStop 27,4% Snoops-Trading
3 Porsche 11,1% Zinsfuß
4 Teladoc Health 8,4% Nordstern
5 Airbnb 5,8% World's Best Brands

The "Fear of Missing Out" – FOMO for short – leads traders to buy stocks whose price has already risen significantly. Among others, Verbio rose significantly last week. After a significant correction in February and March, which affected the entire renewable energies sector, the stock is currently trading at an all-time high. The stock price has thus increased more than fivefold over the year. In the last seven days alone, Verbio was traded 242 times on wikifolio.com. 60 per cent of these trades were buys. The biofuel producer is represented e.g. in Tobias Mädchen's wikifolio The Greenvestor World. In a commentary, the trader refers to a current analyst opinion: "Private bank Hauck & Aufhäuser raised its price target for Verbio from 47 to 56 euros and left its rating at 'Buy'. Anticipating additional investments, especially in biomethane, it has raised its forecast for the biofuels producer's medium-term growth rate, analyst Alina Köhler wrote in a research note released Wednesday. Verbio remains a particularly compelling investment idea for her, she added."

Buying the Dip: Buys when prices fall

# Name Performance 7 days bought in this wikifolio, among others
1 Flatexdegiro -1,4% Nebenwerte Europa
2 Norwegian Air Shuttle -48,2% Snoops-Trading
3 Nanorepro -17,1% Special Situations long/short
4 Great Panther Mining -21,7% Aktien Zukunft Chance.
5 Uipath -5,6% 10X Trendfolge-Trading

The "buying the dip" trading motive is evident when traders buy falling stocks in the hope of a bottoming out – in other words, the imminent turnaround. The stock of the online broker flatexDEGIRO can be assigned to this category. However, the paper lost only slightly on a weekly basis. After an incredibly strong rally since the stock markets marked the Corona pandemic low in March last year, flatexDEGIRO failed twice at the previous high of around 112 euros in recent weeks. Last week, too, traders have now bought the stock again, hoping that the old high could finally be overcome. At least from a chart perspective, there should not be much standing in the way of a further increase at that point.

Taking Profit: Selling when prices are rising

Everything is relative on the stock exchange. Whether a stock makes profits or losses or rises or falls is always a matter of perspective – or more correctly: the time window. A case in point: while Ballard Power’s stock is in the "taking profit" category this week, traders could just as easily abandon the sinking ship here. For Ballard Power, like the entire industry, has been on a downward slide since the beginning of February. Only the past two weeks were able to bring a slight recovery. Richard Schmutzler, for example, took advantage of this favorable moment in his wikifolio Snoops-Trading and recently sold a portion of the stock at a profit.

Jumping the Ship: Selling when prices are falling

# Name Performance 7 days sold in this wikifolio, among others
1 Curevac -6,6% Gecko Alpha Trend following
2 mVISE -12,8% Global Top20
3 Exasol -9,5% Small Caps
4 Encavis -4,3% Tradingchancen dt. Nebenwerte
5 Alibaba Health -8,4% Wachstumsperlen

Selling when prices are falling – this is what characterizes the "Jumping the Ship" category. Last week, for example, Curevac suffered this fate. 55 percent of all trades in the past seven days were sells. In the longer term, however, Manfred Wagner who holds the stock in oekethic Nachhaltigkeit believes the company has a lot of potential: "Now that the U.S. demand to release the Corona vaccine patents has become public, Curevac's stock price is also slipping. The company from Tübingen does not have a generally approved Corona vaccine yet, but that doesn't matter. It is pulled right down with it. However, Curevac's business, in my view, is not causally done with the Corona vaccine. I like to repeat myself here – as the inventor of mRNA technology, Curevac is sitting on a huge wealth of knowledge about mRNA and the technology for this offers almost unlimited possibilities. Patience will certainly pay off here in the future. You just have to sit out the price turbulences."


Disclaimer: Every investment in securities and other forms of investment is subject to various risks. Explicit reference is made to the risk factors in the prospectus documents of Lang & Schwarz Aktiengesellschaft (Final Terms, Base Prospectus together with supplements and the Simplified Prospectuses, respectively) at wikifolio.com , ls-tc.de and ls-d.ch. You should read the prospectus before making any investment decision in order to fully understand the potential risks and rewards of the decision to invest in the securities. The approval of the prospectus by the competent authority should not be construed as an endorsement of the securities offered or admitted to trading on a regulated market. The performance of the wikifolios as well as the respective wikifolio certificates refers to past performance. Future performance cannot be inferred from this. The content of this site does not constitute investment advice or a solicitation to buy or sell securities. This applies in particular to countries in which such an offer to buy or sell is not permitted. For further information, please refer to our General Terms and Conditions.